New research reveals hope for treating psychopathy in younger individuals

Psychopathy affects around 1% of the general population but is linked to a large proportion of violent crime. Those with the condition often struggle to feel guilt, show little empathy, and can appear charming yet manipulative. For decades, treatments have had mixed success, but newer research suggests some interventions may help—especially for younger individuals.

Early attempts to treat psychopathy were harsh and ineffective. From 1965 to 1978, the so-called total encounter capsule method used force and humiliation, failing to produce lasting change. Even later approaches, such as cognitive behavioural programmes in prisons, only showed modest reductions in reoffending for people with or without psychopathic traits.

More recent studies offer cautious optimism. A 2019 experiment found that individuals with higher psychopathic traits showed less pupil dilation when viewing fearful faces, reinforcing the idea of blunted emotional responses. However, newer therapies like dialectical behaviour therapy have succeeded in reducing self-harm among those with borderline personality disorder, while mentalisation-based treatment has cut aggressive behaviour in people with antisocial personality disorder.

Despite these advances, no scientifically evaluated therapy exists specifically for adult psychopaths in German or EU prisons. Programmes like Building Choices, which focuses on cognitive-behavioural skills, and mentalisation-based treatment, which improves understanding of others' mental states, target broader antisocial behaviours rather than psychopathy itself. Yet researchers now believe early intervention, particularly in young people, could make a difference.

While no single treatment has been proven to address psychopathy directly, some modern approaches show promise in managing related behaviours. The focus remains on reducing harm, particularly in younger individuals, where interventions appear most effective. Further research is needed to develop targeted therapies for adults with psychopathic traits.